Replimune's RP1 Carcinoma Trial Fails to Meet Primary Endpoints

By Dean Seal A clinical trial of Replimune Group's RP1 as a treatment for cutaneous squamous cell carcinoma failed to meet its primary endpoints. The...

Related Keywords

,Replimune Group ,Dean Seal ,Article Normal ,Pharmaceuticals ,Vaccines ,Healthcare Life Sciences ,Specialized Drugs Medications ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Cancer ,Political General News ,Health ,Medical Conditions ,Skin Cancer ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Trepl ,Us76029n1063 ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,